The LONGEVITY project is developing long-acting medicines intended for the prevention of malaria and tuberculosis, as well as a single-injection cure for the hepatitis C virus. New medicines we create will be deployed in low- and middle-income countries (LMICs) where the burden is highest, with an estimated 300 million people infected and more than two million deaths per year.

A critical issue in treating or preventing these diseases is poor adherence to daily medication. This can be caused by a number of factors such as stigma around the disease, pill burden, and complex delivery modes. These difficulties can be overcome and adherence to life saving medication improved, by replacing chronic oral dosing with an injectable alternative that requires administration far less frequently.

Our aims

• Reduce the huge burden unsustainable oral regimens place on patients by reformulating pre-existing medicines as long-acting formulations that require administration far less frequently
• Transform healthcare programmes as we expand global knowledge in long-acting injectable product development, regulation of the technology, and how it should be implemented by healthcare providers
• Improve the quality of care for millions of people on a global scale through our world-leading research in materials chemistry and pharmacology, as well as regulatory expertise and community engagement.